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Abstract
Purpose of review: The purpose of this review is to report how administrative data have been used to study AKI,
identify current limitations, and suggest how these data sources might be enhanced to address knowledge gaps in
the field.
Objectives: 1) To review the existing evidence-base on how AKI is coded across administrative datasets, 2) To
identify limitations, gaps in knowledge, and major barriers to scientific progress in AKI related to coding in
administrative data, 3) To discuss how administrative data for AKI might be enhanced to enable “communication”
and “translation” within and across administrative jurisdictions, and 4) To suggest how administrative databases
might be configured to inform ‘registry-based’ pragmatic studies.
Source of information: Literature review of English language articles through PubMed search for relevant AKI
literature focusing on the validation of AKI in administrative data or used administrative data to describe the
epidemiology of AKI.
Setting: Acute Dialysis Quality Initiative (ADQI) Consensus Conference September 6-7th, 2015, Banff, Canada
Patients: Hospitalized patients with AKI
Key messages: The coding structure for AKI in many administrative datasets limits understanding of true disease
burden (especially less severe AKI), its temporal trends, and clinical phenotyping. Important opportunities exist to
improve the quality and coding of AKI data to better address critical knowledge gaps in AKI and improve care.
Methods: A modified Delphi consensus building process consisting of review of the literature and summary
statements were developed through a series of alternating breakout and plenary sessions.
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Results: Administrative codes for AKI are limited by poor sensitivity, lack of standardization to classify severity, and
poor contextual phenotyping. These limitations are further hampered by reduced awareness of AKI among
providers and the subjective nature of reporting. While an idealized definition of AKI may be difficult to implement,
improving standardization of reporting by using laboratory-based definitions and providing complementary
information on the context in which AKI occurs are possible. Administrative databases may also help enhance the
conduct of and inform clinical or registry-based pragmatic studies.
Limitations: Data sources largely restricted to North American and Europe
Implications: Administrative data are rapidly growing and evolving, and represent an unprecedented opportunity
to address knowledge gaps in AKI. Progress will require continued efforts to improve awareness of the impact of
AKI on public health, engage key stakeholders, and develop tangible strategies to reconfigure infrastructure to
improve the reporting and phenotyping of AKI.
Why is this review important?: Rapid growth in the size and availability of administrative data has enhanced the
clinical study of acute kidney injury (AKI). However, significant limitations exist in coding that hinder our ability to
better understand its epidemiology and address knowledge gaps. The following consensus-based review discusses
how administrative data have been used to study AKI, identify current limitations, and suggest how these data
sources might be enhanced to improve the future study of this disease.
What are the key messages?: The current coding structure of administrative data is hindered by a lack of
sensitivity, standardization to properly classify severity, and limited clinical phenotyping. These limitations combined
with reduced awareness of AKI and the subjective nature of reporting limit understanding of disease burden across
settings and time periods. As administrative data become more sophisticated and complex, important opportunities
to employ more objective criteria to diagnose and stage AKI as well as improve contextual phenotyping exist that
can help address knowledge gaps and improve care.
ABRÉGÉ
Article synthèse: Cette revue vise à rendre compte de la manière dont les données administratives ont été
utilisées jusqu’à maintenant pour l’étude de l’insuffisance rénale aiguë (IRA). On a également voulu définir les limites
actuelles et suggérer une manière dont les sources de données pourraient être améliorées pour pallier les lacunes
des connaissances dans ce domaine.
Objectifs de la revue: Cette revue visait plusieurs objectifs:
1) Répertorier les données probantes sur la manière dont l’IRA est codée dans les ensembles de données
administratives.
2) Identifier les limites, les lacunes au niveau des connaissances et les principaux obstacles aux avancées de la
science relevant de la codification de l’IRA dans les données administratives.
3) Discuter de la façon dont les données administratives relatives à l’IRA pourraient être bonifiées afin de favoriser
leur transmission au sein des différents secteurs de compétences.
4) Suggérer une nouvelle façon de configurer les bases de données administratives afin qu’elles puissent servir de
source d’information pour la tenue d’études pragmatiques fondées sur la consultation de registres.
Sources: L’information a été colligée à la suite d’un passage en revue des articles pertinents publiés en anglais sur
PubMed. Les articles portant sur la validation de l’IRA au sein des données administratives ou sur l’usage de celles-ci
pour rendre compte de l’épidémiologie de l’IRA ont été retenus.
Cadre de la revue: La revue a eu lieu dans le cadre de la 15e réunion annuelle de concertation de l’Acute Dialysis
Quality Initiative (ADQI) qui s’est tenue les 6 et 7 septembre 2015 à Banff, au Canada.
Population observée: Les cas retenus pour la revue sont ceux de patients hospitalisés atteints d’IRA.
(Continued on next page)
Siew et al. Canadian Journal of Kidney Health and Disease  (2016) 3:12 Page 2 of 12
(Continued from previous page)
Points saillants: La façon dont l’IRA est codée au sein des ensembles de données limite la compréhension réelle
du fardeau que représente cette maladie, particulièrement pour les patients atteints moins sévèrement. Il semble
également que l’on ne puisse identifier correctement les tendances temporelles ni le phénotype clinique de l’IRA
parmi ces données. On a aussi constaté qu’il existe d’importantes possibilités d’amélioration de la codification de
l’IRA dans les ensembles de données pour arriver à mieux cerner les lacunes dans la connaissance de la maladie et
bonifier les soins prodigués aux patients.
Méthodologie: Une version adaptée de la méthode Delphi pour l’atteinte d’un consensus a été utilisée pour
produire le compte-rendu. La revue de la littérature et des récapitulatifs ont été élaborés à la suite d’une série de
discussions alternant entre des ateliers en petits groupes et des séances plénières.
Résultats: Les codes administratifs concernant l’IRA sont limités en raison du faible taux de rappel des documents
pertinents lors des recherches, du manque de normalisation dans le classement de la sévérité de la maladie et de la
faible identification de son phénotype. Ces limites sont de plus freinées par un manque de sensibilisation des
fournisseurs de soins de santé face à l’IRA et par le caractère subjectif d’un signalement volontaire des cas observés.
Bien qu’une définition idéalisée de l’IRA soit difficile à mettre en œuvre, améliorer la normalisation des signalements
en se basant sur un consensus scientifique et fournir de l’information quant au contexte où se manifeste l’IRA sont
possibles. Les bases de données administratives peuvent améliorer les pratiques entourant la conduite d’études
cliniques ou d’études pragmatiques basées sur la consultation de registres, et servir de sources d’informations pour
celles-ci.
Limites de la revue: La provenance des sources consultées pour cette revue se limite en grande partie à
l’Amérique du Nord et à l’Europe.
Conclusions: La croissance et l’évolution rapide des bases de données administratives représentent une occasion
unique de s’attaquer aux lacunes dans les connaissances sur l’IRA. L’avancement de ces connaissances demandera
le déploiement d’efforts constants pour favoriser la prise de conscience des répercussions de cette maladie sur la
santé publique. Cela demandera aussi l’engagement des principaux intervenants ainsi que la mise en place de
stratégies concrètes visant la reconfiguration des infrastructures existantes et l’amélioration de la collecte de
données et de l’identification du phénotype de l’IRA.
Background
The clinical study of acute kidney injury (AKI) has
been facilitated in recent years by the increasing
availability of administrative data. The housing of vast
amounts of information in accessible data warehouses
and the relatively low cost of procurement suggest
potential usefulness. However, as usually not collected
for conducting clinical research, concerns over the
quality of the data and its ability to fill knowledge gaps
and evaluate quality of care have been raised [1, 2]. On
September 6th, 2015, the Acute Dialysis Quality Initia-
tive (ADQI) convened a panel of experts in nephrology,
critical care, pharmacology, pediatrics, epidemiology,
health services research and data analytics from five
countries from North American and Europe to examine
how rapidly evolving clinical data infrastructures in the
era of ‘big data’ can be leveraged to enhance scientific
progress and improve outcomes in patients with AKI.
Here, we review how administrative data have been
used to study AKI, identify current limitations, and
suggest how these data sources might be enhanced to
address knowledge gaps in the field. We present four
key questions regarding the use of administrative data
for research and quality improvement; and then a
corresponding series of consensus statements devel-
oped through reviewing the literature and iterative
discussion.
Methods
The ADQI methodology has been previously detailed
[3]. In brief, the consensus-building process was in-
formed by pre-conference, conference, and post-
conference review of English language articles through
PubMed search for relevant AKI literature. We selected
articles if they focused on the validation of AKI in ad-
ministrative data or used administrative data to describe
the epidemiology of AKI.
We conducted a 2-day conference in September 2015
in Banff, Canada, where summary statements were de-
veloped through a series of alternating breakout and
plenary sessions. Panelists were assigned to 3–5 person
workgroups. In each breakout session, the workgroups
refined the key questions, identified the supporting evi-
dence, and generated consensus statements. Workgroup
members presented their findings during the plenary
sessions and then revised their drafts as needed until a
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final version was agreed upon. A writing committee as-
sembled the individual reports from the workgroups and
each report was edited to conform to a uniform style
and for length. The final reports were provided to each
participant for comment.
Review
Question #1: What is the existing evidence-base for
how AKI is coded across various administrative
datasets?
Consensus Statement #1A: Administrative data are
defined as information collected and stored for patient
or disease registration, to inform transactions, or to
promote other record keeping. The coding of AKI
using these data sources has utilized billing/claims,
limited laboratory-based definitions in disease-
specific registries, and population-based health
registries.
Consensus Statement #1B: Commonly used
administrative codes for AKI generally demonstrate
poor sensitivity and high specificity.
For this manuscript, we will define health care-related
administrative data as information collected and stored
for patient disease registration, to inform transactions,
or perform other record keeping (http://www.adls.ac.uk/
adls-resources/guidance/introduction/).
Major producers of administrative data include, but
are not limited to, governmental agencies (e.g., Federal,
State/Provincial, and Veterans Affairs), insurers, and
healthcare systems. Most literature using administrative
data to study AKI have applied the 9th and 10th iterations
of the International Classification of Disease, Clinical
Modification (ICD-9-CM, ICD-10-CM) and procedure
codes and the American Medical Association’s Current
Procedural Terminology (CPT) codes to capture the diag-
nosis of AKI and renal replacement therapy (RRT) [2, 4].
Within these classification systems, AKI is most commonly
coded as Acute Kidney Failure with various histologic
descriptors (Table 1). The latter are generally based on
clinical impression as confirmatory histologic diagnosis
requires kidney biopsy, something rarely pursued in clinical
practice. Further these histologic diagnoses have tradition-
ally been non-exhaustive and include distinctions of less
clear relevance (e.g. tubular versus medullary necrosis).
While subsequent iterations (ICD-10) have broadened to
capture additional lesions of interest (e.g. acute tubulo-
interstitial nephritis), they remain independent codes that
do not readily link to major AKI codes and little data is
available reflecting their performance against either an
Table 1 Examples of Administrative codes for AKI
ICD-9-CM ICD-10 Name
584 N17 Acute kidney failure
584.5 N17.0 Acute kidney failure with lesion of tubular necrosis
584.6 N17.1 Acute kidney failure with lesion of renal cortical necrosis
584.7 N17.2 Acute kidney failure of renal medullary (papillary) necrosis
584.8 N17.8 Acute kidney failure with other specified pathological lesion in the kidney
584.9 N17.9 Acute kidney failure, unspecified
593.9 N28 Unspecified disorder of kidney and ureter
N28.0 Ischemia and infarction of the kidney
N28.9 Disorder of kidney and ureter
583.00-90 N00.xN01.xN05.2,5,8,9 ICD- 9: Nephritis and nephropathy, not specified as acute or chronic with lesion of
….ICD-10: Acute Nephritic syndrome (N00) with…Rapidly progressive nephritic
syndrome (N01) withUnspecified nephritic syndrome (N05) with…
669.30,32,34 O09.4 ICD-9 Acute kidney failure following labor and delivery…
N99.8 Postprocedural (acute)(chronic) kidney failure
O04.82 Renal failure following (induced) termination of pregnancy
O07.32 Renal Failure following failed attempted termination of pregnancy
N10 Acute tubulo-interstitial nephritis
N14.0-4 Drug- and heavy-metal-induced tubule-interstitial and tubular conditions (acuity not specified)
The most commonly studied and used codes are bolded
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adjudicated or histologic standard. Lastly, most adminis-
trative coding datasets do not provide a standardized ap-
proach to staging of severity outside of recording dialysis.
Disease or procedural registries also report data on renal
failure, occasionally collecting serum creatinine data. How-
ever, definitions for AKI in such registries tend to focus on
the most severe phenotypes, may not distinguish between
acute or chronic disease, or harmonize with modern con-
sensus definitions. For example, the National Surgical
Quality Improvement Program (NSQIP) and American
College of Surgeons Committee on Trauma have tradition-
ally defined AKI as a rise in serum creatinine above 2 mg/
dl (177 μmol/l) or dialysis and a serum creatinine above
3.5 mg/dl (309 μmol/l), respectively [5–7]. This hetero-
geneity may hinder comparisons and underestimate
disease burden. Recent efforts to recalibrate renal failure
definitions, however, may indicate greater acceptance of
standardized definitions in some of these data sources.
For example, the Society of Thoracic Surgeon database
recently changed from a threshold creatinine of > 2 mg/dl
(177 μmol/l) to define AKI to incorporate the RIFLE classi-
fication system (http://www.sts.org/sites/default/files/docu
ments/Training%20Manual%20for%20website_2.pdf).
Coding performance has been examined in several
studies by comparing them to a reference standard of
creatinine change or manual chart review [8–11].
Vlasschaert et al. performed a systematic review examin-
ing the diagnostic accuracy of ICD-9 and ICD-10 codes
in US and Canadian datasets between 1987 and 2004
[8]. Despite variations in the reference standards used
(varying creatinine-based definitions of AKI or chart re-
view), sensitivity was generally low (median 29 %; range
15-81 %) though specificity remained high (>94 % in all
datasets examined). This performance translated to high
negative predictive values with variable positive predict-
ive values depending on the cohort examined and
underlying prevalence of AKI (between 0.5-52 %). Des-
pite having a lower prevalence of chronic kidney disease,
sensitivity in children for AKI is also poor. A recent
study found that administrative data had poor sensitivity
(21-23 %) for detecting nephrotoxin-associated AKI in
children who had serum creatinine monitored daily [12].
Performance between US and Canadian datasets were
similar, although sensitivity was slightly higher in Canad-
ian datasets. Restriction to dialysis-requiring AKI gener-
ally improved validity, but not always. For example,
Waikar et al. found that the combination of any Acute
Kidney Failure code (574.5-9) and hemodialysis proced-
ure codes produced high sensitivity (90.4 %) and specifi-
city (93.8 %) for detecting dialysis-requiring AKI as
verified by chart review in Boston-area teaching hospi-
tals (USA) between 1988–2002 [13]. However, more re-
cently, Grams et al. used a similar approach to examine
the performance of administrative codes for dialysis-
requiring AKI in a select cohort of participants of The
Atherosclerosis Risk in Communities (ARIC) study hos-
pitalized in Washington County, Maryland between
1996–2008 [11]. In this study, specificity for the dialysis-
requiring AKI coding algorithm was high (99.9 %)
but had lower sensitivity (36.5 %). Lastly, there is evi-
dence that performance can change over time. For ex-
ample, several studies have demonstrated that the
sensitivity of billing codes has improved in recent years
but generally remains modest. [10, 11, 13]
The collective performance of administrative codes for
detecting AKI, particularly when not directly linked to
serum creatinine, has important implications. For ex-
ample, poor or changing sensitivities limit value in un-
derstanding true disease burden; provide overly
conservative estimates of disease prevalence, skew tem-
poral trends due to changes in the sensitivity of diagnos-
tic codes, and contain uncertainty in distinguishing
acute from chronic disease. The relative high specificities
may make current administrative data more amenable to
examining outcomes of patients identified with AKI.
However, positive predictive value may vary depending
on the underlying risk of the population studied and the
severity detected may also vary across regions or time.
Question #2: What are the limitations, gaps in
knowledge, and major barriers to scientific progress in
AKI related to how AKI is coded?
Consensus Statement 2a: Major limitations of current
administrative data include poor awareness of AKI
and the subjective nature of its assessment, lack of
information on severity, and the use of non-consensus
criteria for defining and staging AKI.
Consensus Statement 2b: Major knowledge gaps in
AKI using current administrative data sources include,
but are not limited to, lack of contextual phenotyping,
information on complications including dialysis-
dependence or other indicators of recovery, and coding
structure and performance in non-North American
registries.
Limitations of administrative data
Figure 1 shows the current strengths, limitations, oppor-
tunities, and threats to optimal use of administrative
datasets for examining AKI. In addition to strengths
listed, we identified several factors contributing to the
limited performance of current administrative coding.
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One major limitation likely contributing to the low
sensitivities observed is poor provider awareness. Accur-
ate and sensitive reporting of AKI depends on recogni-
tion that 1) AKI has occurred and 2) it was clinically
relevant. As most AKI does not require dialysis and not
linked to a procedure code, coding becomes wholly
dependent on provider recognition. AKI is generally
well-recognized by nephrologists or other experts, how-
ever, primary diagnosis codes for patients requiring
acute care are most often entered by providers or coding
personnel with less expertise or interest in the area.
While consensus criteria have likely improved aware-
ness, overall sensitivity remains modest. [11] The result-
ing discrepancy between exposure and awareness
contributes to underreporting of disease (Fig. 2), under-
scoring the need for improved dissemination of data re-
garding the short- and long-term clinical implications of
AKI to a broader audience [14].
Subjective coding may also be influenced by external
forces, including patient related factors (i.e. patient com-
plexity), variations in practice and coding patterns across
medical disciplines, geography, and practice settings. For
example, capturing AKI in a critically ill patient with
prolonged hospitalization, multi-system organ failure,
and contributing comorbidities requires overcoming
substantial coding ‘inertia’. In addition, while sensitivity
has improved, the resulting changes make interpreting
temporal trends challenging. For example, uncertainty
exists as to whether increases in disease incidence and
improvement in survival observed are attributable to
better reporting of less severe AKI, changes in case-mix
(e.g. more acute on chronic disease), or true improve-
ments in care [13, 15]. Similarly, variations in treatment
may affect underlying assumptions in classifying AKI.
For example, dialysis-requiring AKI has traditionally
been considered the most severe form of AKI. However,
thresholds to initiate dialysis may vary depending on
situation or over time that can violate that assumption.
For example, a mildly volume depleted patient dialyzed
for lithium intoxication may not have severe AKI and
evidence for earlier application of RRT in recent years
may indicate a trend toward dialyzing less severe injury
[16]. A lack of readily accompanying information (e.g.,
indication or stage) in these situations often hinders the
ability to make these important distinctions.
How improving upon coding limitations may help
address current knowledge gaps in AKI
It remains possible to enhance administrative data to ad-
dress critical knowledge gaps in AKI. For example, an
increased understanding of the changing case-mix of
AKI and its relative impact in different settings is needed
[17]. While novel biomarkers may eventually redefine
phenotyping, opportunities exist to provide additional
contextual information. For example, as AKI most often
occurs due to underlying illness, it is most often pheno-
typed based on the setting in which it occurs. Thus, link-
ing the diagnosis of AKI as a complication of conditions
Fig. 1 Strength, Weaknesses, Opportunities, and Threat (SWOT) Analysis of Current Administrative Codes for AKI. Source: Acute Dialysis Quality
Initiative 15 www.adqi.org; used with permission
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including sepsis (e.g. ‘sepsis complicated by AKI’, ‘con-
trast/chemotherapy-associated AKI’), might help over-
come the inertia of coding AKI as a separate entity and
harmonize with how most AKI is conventionally pheno-
typed (i.e. by clinical context rather than histology).
Further phenotyping of AKI severity and pre-/post-
hospitalization kidney function may better understand-
ing of the role of AKI on the natural history of kidney
health and disease progression. However, lack of quality
information on pre-morbid kidney function, inpatient
trajectory, and post-AKI kidney function in current ad-
ministrative datasets introduce uncertainty into analyses.
Integration or linkage of data from advancing electronic
health records would enable use of unified diagnostic
criteria, distinguishing relative contributions from AKI
and CKD, improve further critical phenotyping of AKI
(e.g. community-versus-nosocomial acquired AKI, cre-
atinine trajectory, duration, recovery trends), and exam-
ine future outcomes.
Barriers to improving administrative coding
Integrating unified diagnostic criteria and providing con-
textual information will require some reconfiguration of
existing infrastructure. Key stakeholders including
payers, government, providers, and coders will need to
be engaged and convinced that doing so will improve
costs and quality by providing a fuller understanding of
disease burden, help to identify patients at high risk for
the sequelae of AKI, and opportunities to examine care.
Meaningful changes in coding infrastructure in the
kidney disease space are not without precedent. In 2005,
the Kidney Disease Outcomes Quality Initiative
(KDOQI) staging system for CKD was incorporated into
the ICD-10 coding structure. The impetus for these
changes in the US was provided by the National Center
for Health Statistics, National Kidney Foundation, and
the Renal Physicians Association whose goals were to
improve understanding of disease burden, follow pa-
tients longitudinally, understand treatments provided,
and assess the quality of care being delivered. More re-
cent examples of mutual engagement include ongoing
initiatives between the critical care community in
Canada and the Canadian Institute for Health Informa-
tion (CIHI) to develop a standardized structure for
reporting critical care capacity, operations, quality, and
outcomes data. This collaboration will enable a national
description of critical care utilization, quality indicators
and outcomes aimed at driving health systems improve-
ments. Another current example that model such im-
provements include the National Health Services ‘Think
Kidneys’ program in the United Kingdom [18]. By coup-
ling electronic alerting embedded in all hospitals to im-
prove the recognition of AKI and reduce variability in
ascertainment and reporting, developing this critical in-
frastructure has enabled the building of a prospective
Fig. 2 Relative Differences in Scope of AKI Cared and Coded for by Provider Type. The pyramid on the left represents the full burden of AKI seen
by non-nephrologists with the relative prevalences of mild, moderate-severe, and dialysis-requiring AKI indicated by shading. In contrast, while
nephrologists are more likely to code for less severe AKI, they will encounter a more select population of AKI patients favored by highly severe
stages. Source: Acute Dialysis Quality Initiative 15 www.adqi.org; used with permission
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registry to capture data on all patients with AKI in a
standardized fashion and link to a larger National Renal
Registry.
A non-diagnosis related barrier is the deliberate transi-
tion of medical records to digital filing. Although the
American Reinvestment and Recovery Act of 2009 man-
dated use of EHRs, integration across institutions in the
United States has taken longer than anticipated leading to
variability in the extractability of information (as some
data remains in paper charting). Additionally, the coding
structure and performance for capturing AKI in systems
outside of the US, Canada, and UK are underreported.
These inconsistencies negatively impact the reliability of
administrative datasets across registries and limit the abil-
ity to do cross-institutional/-country comparisons.
Finally, a down-stream concern related to changes
in coding is the potential for negative reimbursement
for ‘nosocomially-acquired AKI’. As value based pur-
chasing and quality-based reimbursements by both in-
surance agencies and governmental emerge (e.g., US),
granularity in AKI diagnosis with regards to the eti-
ology of injury could actually dissuade clinicians from
coding for AKI (e.g., contrast nephropathy induced
AKI may be deemed a nosocomial AKI and therefore
not reimbursed). Avoidance of this problem will re-
quire involvement of relevant stakeholders to ensure
appropriate quality metrics that do not penalize ac-
curate diagnostic coding.
Questions #3: What would be the ideal minimal
definition for AKI in administrative databases to
enable “communication” and “translation” within and
across administrative jurisdictions (i.e., institutional,
regional, national, international)?
Consensus Statement #3: The ideal definition of AKI
in administrative databases that would enable cross-
registry communication would include descriptors of
the onset, duration, severity, context, histology, progres-
sion, and recovery of AKI. Minimum essential elements
include a standardized, objective description of AKI se-
verity (i.e., stage) accompanied by complementary in-
formation on the context in which AKI occurs.
Definitions of AKI have evolved over the past 20 years
as stakeholders have begun to appreciate the benefits of
consensus, both for clinical management and for re-
search. The achievement of standardized definitions (e.g.,
RIFLE, AKIN, KDIGO) has advanced the field by providing
a platform for communication and comparison [19–21].
While emerging evidence indicates that clinicians are be-
ginning to use these consensus criteria in quality
improvement initiatives [22, 23], widespread evidence of its
penetration into administrative datasets is lacking.
An ideal “administrative” definition of AKI would incorp-
orate factors that describe the onset, duration, severity, con-
text, histology, progression, and recovery of AKI (Fig. 3).
Limitations in current clinical phenotyping and the practi-
cality of standardizing all of these elements as discussed
above place some feasibility restrictions on this idealized
goal for the near future. However, these limitations do not
preclude attainable progress.
Two areas identified where improvements are cur-
rently possible include improving coding of AKI severity
and providing contextual information for the setting in
which AKI occurs (Fig. 3 red oval). Introduction of the
KDIGO classification system for AKI including “mild”
(stage 1), “moderate” (stage 2) and “severe” (stage 3) AKI
would enhance capture and phenotyping of AKI beyond
the binary system currently in place. As AKI diagnosis
relies heavily on laboratory data, the fidelity of these sys-
tems will be improved greatly and lend themselves to
true standardization through automated inclusion of la-
boratory data as research networks evolve to integrate
large volumes of EHR, administrative, and registry data
sources. The latter would also enhance the ability to dis-
tinguish between chronicity, onset (community versus
hospital-acquired), and permit longitudinal phenotyping
including recovery.
Similarly, current AKI coding systems should be
modified to provide additional contextual informa-
tion in which AKI occurs. A natural extension would
be to include AKI as a complication of known major
precipitants (e.g., sepsis, contrast, cirrhosis, cardiac
surgery) as is currently the case for CKD coding al-
gorithms (e.g., diabetes mellitus with diabetic chronic
kidney disease, hypertensive chronic kidney disease).
As most cases will not be seen by nephrologists, this
structure may also have the added benefit of improv-
ing sensitivity as clinicians are more likely to con-
sider AKI if linked to the primary disease rather
than overcoming the effort to code it as a separate
entity.
In summary, limitations in the current clinical pheno-
typing of AKI should not prevent tangible improvements
to the current coding of AKI. The reliance of physio-
logic and laboratory data for AKI diagnosis should
prompt progressive consideration for automatic capture
and inclusion as administrative datasets evolve.
Question #4: How can administrative databases be
configured to inform “registry-based” pragmatic
studies?
Consensus Statement #4A: Administrative databases
can be used to identify and enrich target populations
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of interest and inform the feasibility and power of
trials.
Consensus Statement #4B: Patients enrolled in clinical
trials can be potentially linked to administrative
databases to enhance outcome ascertainment, reduce
costs, and examine additional outcomes of interest if
patient identifiers are available.
Administrative databases, particularly if enhanced by
improvements in coding and accuracy, can be leveraged
to inform clinical studies or facilitate registry-based
pragmatic studies (Fig. 4). First, administrative databases
can help inform study design by refining inclusion and
exclusion criteria. Analysis of characteristics that identify
patients with, or who are likely to develop AKI and its
sequelae, can refine the approach to targeting of
Fig. 4 Schematic Illustrating Potential Leveraging of Administrative Data for Clinical Trials. Given limitations in time of reporting and sensitivity,
administrative data may be best suited to facilitate the planning and follow-up stages of a putative randomized or pragmatic trial, though disease or
procedure-specific registries may be able to be used as a ‘real-time’ tool to guide enrollment or intervention. Source: Acute Dialysis Quality Initiative 15
www.adqi.org; used with permission
Fig. 3 Elements of an “Ideal” Definition of AKI Potentially Captured in Future Administrative Data. An idealized future definition of AKI would
include descriptive elements able to identity cause, severity, chronicity, type, timing, and context. Given current limitations in clinical phenotyping
and coding structure, severity of injury and the context in which it occurs (e.g. cardiac surgery, sepsis, contrast) may be the best initial targets to
pursue. Source: Acute Dialysis Quality Initiative 15 www.adqi.org; used with permission
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patients, estimate study feasibility, and project event
rates and sample size.
Poor recruitment can hamper trials [24]. Identifying
sites with high volumes of patients meeting inclusion
criteria allows for targeted collaboration across locations
and could improve recruitment. Assessment of event
rates can also reduce the need for mid-study adjust-
ments in sample size [25]. The use of large databases for
such practices is well illustrated by the design of the
PROMISE trial; this trial of early-goal directed therapy
for severe sepsis patients in the United Kingdom accur-
ately predicted in-hospital mortality in the control arm
based on preliminary assessment of the Intensive Care
National Audit and Research Centre (ICNARC) Case
Mix Programme Database, a registry of intensive care
patients in the United Kingdom [26]. It is important to
note that this use of administrative data to inform stud-
ies related to AKI requires a clear knowledge of the
quality of the data. Datasets with poor sensitivity but
high specificity for AKI may be better suited to examine
outcomes in populations with moderate to severe AKI
rather than those at risk or with mild AKI. Such limita-
tions do not preclude the use of administrative data for
these purposes, but do limit the ways they may be used.
Another potential benefit of administrative data in clin-
ical studies is the ability to enhance follow-up of patients
already enrolled in studies [27]. Administrative data that
provide longitudinal information or can be readily linked
through available identifiers to other outcome registries
(death, ESRD) can be a powerful and cost-saving tool to
augment long-term follow up to determine basic outcome
information such as mortality, or dialysis. Administrative
data can also provide information on other important out-
comes such as long-term healthcare resource use by indi-
viduals following an intervention as well as cost data. The
latter may be an important tool as larger trials are pro-
posed and follow-up of individuals becomes prohibitively
expensive, particularly among studies where patients may
be more difficult to track using traditional means such as
telephone interviews or surveys.
Notably, some administrative databases may be “locked”
in terms of the data available in them (e.g. Medicare) that
may preclude use for tracking specific outcomes. For ex-
ample, some select adverse events used as surrogate or part
of a composite outcome may require more detailed infor-
mation for adjudication (e.g. post-operative myocardial in-
farction) that available. However, other administrative
databases may have some flexibility in terms of adding data
fields for the purposes of a clinical study. An example of
this might be the addition of the type and duration of dialy-
sis in a registry of ICU patients that normally only requires
inclusion of a binary variable for dialysis.
Given the current time lag of data availability in most
administrative datasets, some may be less well-suited to
guide real-time enrollment or randomization of individ-
ual patients during the acute phase of illness. This would
be especially true where information on short-term
events (e.g. hospital mortality) or a greater degree of
granularity to accurately capture process-oriented vari-
ables such as select adverse events or complications are
required in a timely fashion. However, administrative or
registry data may be potentially used in certain situa-
tions. For example, in a cluster-randomized study where
a process of care such as quality improvement or com-
pliance with care bundles (e.g. use of intravenous vol-
ume expansion prior to contrast exposure) is an
outcome, the use of administrative data may be feasible.
More recently developed disease and procedure regis-
tries, such as the APPROACH database, a Canadian
registry of patients undergoing cardiac catheterization
and cardiac surgery, are being used to capture the ma-
jority of process and outcome data for the trial. (Clini-
calTrials.gov Identifier: NCT02096406). Including
research stakeholders within administrative or disease-
registry development or oversight teams may facilitate
their configuration to integrate research and quality im-
provement aims.
Conclusions
In summary, administrative datasets have facilitated the
study of AKI on a population-level and are being leveraged
by an expanding user base. Major limitations currently in-
clude low sensitivity, the subjective nature of assessment,
and limited clinical phenotyping of AKI. These limitations
highlight important opportunities to improve the quality
and coding of data to better address critical knowledge gaps
in AKI and improve care. Refinements in coding and the
potential to link to increasingly sophisticated EMR data
represent key opportunities to advance current administra-
tive data. While an idealized, comprehensive definition of
AKI is not currently tenable, tangible progress can currently
be made and can help refine how AKI is captured and de-
scribed within administrative data. We propose the integra-
tion of standardized classification schemes and the
improvement of linkage of AKI to the clinical context in
which it occurs as feasible, substantial improvements on
current coding. Progress will require continued efforts to
improve awareness of the impact of AKI on public health,
engagement of key stakeholders, and tangible strategies to
reconfigure infrastructure and improve the reporting and
phenotyping of AKI.
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